THC Farmaceuticals Inc
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses. As of June 30, 2015, it had a total of eight machines for public use along the Wasatch F… Read more
THC Farmaceuticals Inc (CBDG) - Net Assets
Latest net assets as of June 2022: $2.19 Million USD
Based on the latest financial reports, THC Farmaceuticals Inc (CBDG) has net assets worth $2.19 Million USD as of June 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.78 Million) and total liabilities ($594.97K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.19 Million |
| % of Total Assets | 78.63% |
| Annual Growth Rate | 39.93% |
| 5-Year Change | 80.15% |
| 10-Year Change | N/A |
| Growth Volatility | 62.63 |
THC Farmaceuticals Inc - Net Assets Trend (2011–2023)
This chart illustrates how THC Farmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for THC Farmaceuticals Inc (2011–2023)
The table below shows the annual net assets of THC Farmaceuticals Inc from 2011 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-09-30 | $2.60 Million | -1.14% |
| 2022-09-30 | $2.63 Million | +19.30% |
| 2021-09-30 | $2.21 Million | +24.41% |
| 2020-09-30 | $1.77 Million | +22.78% |
| 2019-09-30 | $1.45 Million | -19.50% |
| 2018-09-30 | $1.80 Million | +126.60% |
| 2017-09-30 | $792.47K | -0.91% |
| 2016-09-30 | $799.77K | +1665599.79% |
| 2014-09-30 | $-48.02 | -177.25% |
| 2013-09-30 | $-17.32 | -100.27% |
| 2012-09-30 | $6.52K | -85.89% |
| 2011-09-30 | $46.21K | -- |
Equity Component Analysis
This analysis shows how different components contribute to THC Farmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 140156500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.13K | 0.57% |
| Other Comprehensive Income | $645.00K | 20.15% |
| Other Components | $3.99 Million | 124.53% |
| Total Equity | $3.20 Million | 100.00% |
THC Farmaceuticals Inc Competitors by Market Cap
The table below lists competitors of THC Farmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
National Health Scan
PINK:GEGR
|
$122.33 |
|
Amtex Limited
KAR:AMTEX
|
$122.47 |
|
Surya Oil & Gas Corp.
NASDAQ:SURY
|
$123.21 |
|
Pathkey.ai Ltd
AU:PKY
|
$123.41 |
|
Rafex Gold Corp.
PINK:RAFX
|
$121.79 |
|
Bank Maybank Indonesia Tbk PT
JK:BNII
|
$121.78 |
|
Zhuding International Ltd
PINK:ZHUD
|
$121.66 |
|
SHENGLI OIL & GAS
MU:GSG
|
$121.21 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in THC Farmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 3,215,202 to 3,200,226, a change of -14,976 (-0.5%).
- Net loss of 14,976 reduced equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.98K | -0.47% |
| Total Change | $- | -0.47% |
Book Value vs Market Value Analysis
This analysis compares THC Farmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-09-30 | $0.00 | $0.01 | x |
| 2014-09-30 | $0.00 | $0.01 | x |
| 2016-09-30 | $0.05 | $0.01 | x |
| 2017-09-30 | $0.05 | $0.01 | x |
| 2018-09-30 | $0.12 | $0.01 | x |
| 2019-09-30 | $0.12 | $0.01 | x |
| 2020-09-30 | $0.14 | $0.01 | x |
| 2021-09-30 | $0.15 | $0.01 | x |
| 2022-09-30 | $0.18 | $0.01 | x |
| 2023-09-30 | $0.18 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently THC Farmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.86x
- Recent ROE (-0.47%) is above the historical average (-58.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -61.37% | -83.02% | 0.52x | 1.42x | $-32.98K |
| 2012 | -608.87% | -129.80% | 0.59x | 7.94x | $-40.34K |
| 2013 | 0.00% | -110.17% | 0.44x | 0.00x | $-22.11 |
| 2014 | 0.00% | -161.32% | 0.40x | 0.00x | $-25.90 |
| 2016 | -17.02% | -797.26% | 0.01x | 2.19x | $-216.09K |
| 2017 | -0.92% | -56.38% | 0.01x | 2.21x | $-86.55K |
| 2018 | -0.84% | -124.88% | 0.00x | 1.52x | $-196.32K |
| 2019 | -25.47% | -4891.26% | 0.00x | 1.29x | $-694.28K |
| 2020 | -2.58% | -797.95% | 0.00x | 0.99x | $-295.12K |
| 2021 | -0.30% | -376.90% | 0.00x | 1.00x | $-287.25K |
| 2022 | 13.28% | 4269.05% | 0.00x | 0.86x | $105.38K |
| 2023 | -0.47% | 0.00% | 0.00x | 0.86x | $-335.00K |
Industry Comparison
This section compares THC Farmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| THC Farmaceuticals Inc (CBDG) | $2.19 Million | -61.37% | 0.27x | $121.95 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |